Cycle 3: Conference Grants (R13) and Conference Cooperative Agreements (U13)

Sponsor: NIH Due Date: December 12, 2022 Award: The purpose of the NIH Research Conference Grant (R13) is to support high quality scientific conferences that are relevant to the NIH's mission and to the public health. A conference is defined as a symposium, seminar, workshop, or any other organized and formal meeting, whether conducted face-to-face […]

*rolling basis* Healthcare Research by Community Physicians

Sponsor: Physicans' Services Incorporated Foundation *NO DEADLINE - ROLLING BASIS* Award: "To assist physicians practising in a community setting to undertake a review of their practice patterns which would enhance effectiveness of practice and patient care in their own clinic, hospital or region. Grants up to $20,000 are available to cover the costs of the data […]

*Rolling Basis* Health Research Grant

Sponsor: Physician's Services Incorporated *NO DEADLINE - ROLLING BASIS* Award: Funds clinical research which is of direct relevance to patient care, medical education research which assess the post-MD educational environment, and health systems research. The total amount of requested funding may not exceed $100,000 per year or $200,000 over 2 years.

*rolling basis* Targeted Grants in Mathematics and Physical Sciences

Sponsor: Simons Foundation *NO DEADLINE - ROLLING BASIS* Award: The program is intended to support high-risk projects of exceptional promise and scientific importance on a case-by-case basis. A typical Targeted Grant in MPS provides funding for up to five years. The funding provided is flexible and based on the type of support requested in the […]

Cycle 3: NIH Small Business Grants

DUE DATE: JANUARY 5, 2023 Small Business Innovation Research (SBIR): These programs congressionally require eligible governmental agencies to set aside a percentage of their extramural budget so that domestic small businesses can engage in R&D that has a strong potential for technology commercialization. Total costs for Phase I and Phase II usually do not exceed […]